GlassScriptPhysician profile
Don A Dubose
NPI 1336313329
$289,602.46
in general payments reported to CMS, 2019-2025
27 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $22K · 2021: $38K · 2022: $32K · 2023: $48K · 2024: $104K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $143K · Travel and Lodging: $32K · Food and Beverage: $7,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $143,333.00 |
| Travel and Lodging | $31,543.14 |
| Food and Beverage | $7,344.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $238,132.29 | 2019-2025 | Spravato |
| Abbvie INC. | $23,678.52 | 2021-2025 | Vraylar |
| Allergan, INC. | $23,632.28 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $556.29 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $420.61 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $393.41 | 2022-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $333.56 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $321.80 | 2019-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $239.21 | 2024-2025 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $231.88 | 2020-2025 | |
| Axsome Therapeutics, INC. | $223.34 | 2022-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $202.28 | 2019-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $189.30 | 2022-2024 | Quviviq |
| Corium, LLC | $169.48 | 2021-2024 | Azstarys |
| Eisai INC. | $116.27 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $115.78 | 2021-2022 | |
| Noven Therapeutics, LLC | $102.59 | 2024-2025 | Xelstrym, Secuado |
| Alkermes, INC. | $89.00 | 2019-2023 | Lybalvi |
| Almatica Pharma LLC | $87.47 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Neos Therapeutics, LP | $81.84 | 2020-2024 | Adzenys Xr-Odt |
| Shire North American Group INC | $77.80 | 2019 | |
| Bausch Health US, LLC | $74.61 | 2020-2022 | |
| Lundbeck LLC | $52.90 | 2019-2021 | |
| Aytu Biopharma, INC. | $29.49 | 2021 | |
| Sun Pharmaceutical Industries INC. | $23.32 | 2020 | |
| Masimo Corporation | $14.71 | 2020 | |
| Lilly USA, LLC | $12.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Dubose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.